Source link : https://www.newshealth.biz/health-news/treatment-of-oligometastatic-egfr-mutant-lung-cancer/
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic disease. “A lot of patients respond well to current treatment options — whether it is osimertinib [Tagrisso] with or without platinum-based chemotherapy or amivantamab [Rybrevant] with lazertinib [Lazcluze] — but […]
Author : News Health
Publish date : 2024-11-22 15:30:00
Copyright for syndicated content belongs to the linked Source.